TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

6 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Kidney disease

    Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease

    Testing kidney disease drug effects and safety in teens with early CKD

    💵 May compensate

    📍 Instituto de atención Integral de Enfermedades Renales del Estado de Aguascalientes · Aguascalientes, Aguascalientes · Get directions →

    Chronic kidney disease (CKD) is highly prevalent in the state of Aguascalientes, Mexico, particularly among adolescents and young adults. Epidemiologic and histologic studies suggest that this burden is largely driven by reduced nephron endowment of prenatal origin, leading to compensatory glomerular hyperfiltration, adaptive podocytopathy, and persistent albuminuria at early stages of disease.

    ✓ Study care freePhase 4Ages 14–18Learn more →
  • Type 2 diabetesKidney disease

    Mechanism of SGLT2 Inhibition in the Kidney

    Testing how SGLT2 medicines affect kidney function in type 2 diabetes

    💵 May compensate

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    The goal of this open-label, non-randomized clinical trial is to determine what effects, if any, an FDA-approved drug class known as SGLT2 inhibitors (Canagliflozin or INVOKANA) has any protective effects on kidney function in Type 2 diabetes. We are looking for participants 18-80 years of age, who have had a clinical diagnosis of Type 2 diabetes for ≥ 3 years.

    ✓ Study care freePhase 4Ages 18–80Learn more →
  • Crohn's / ulcerative colitis (IBD)

    Treatment of UC With Novel Therapeutics

    Testing an oral medicine to treat mild ulcerative colitis over 12 weeks

    💵 May compensate

    📍 Brigham and Women's Hospital · Chestnut Hill, MA · Get directions →

    This study is a clinical trial being done to investigate the efficacy of drug BRS201 as a treatment in patients with active mild ulcerative colitis. Participation in this study will take 12 weeks long and the study is structured as a crossover study in which participants will take the study drug for 4 weeks and a placebo drug for 4 weeks in a randomized order in the form of an oral medication.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Crohn's / ulcerative colitis (IBD)

    Study of Novel Therapeutics for Acute Remedy of Colitis

    Testing a new treatment in adults with acute ulcerative colitis

    💵 May compensate

    📍 Brigham and Women's Hospital · Chestnut Hill, MA · +1 more US site · Get directions →

    This study is a clinical trial being done to investigate the efficacy of drug BRS201 as a treatment in patients with acute ulcerative colitis. Patients who qualify are adults who have not responded to treatments for their severe ulcerative colitis.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Crohn's / ulcerative colitis (IBD)

    Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD

    Testing whether mirikizumab is safe and works for people with Crohn’s strictures

    💵 May compensate

    📍 Digestive & Liver Center of Florida · Orlando, FL · +1 more US site · Get directions →

    This is an open-label, single-arm, phase 4 study to assess the safety and efficacy of mirikizumab in approximately 60 participants with stricturing CD.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Heart / cardiovascular disease

    Canagliflozin Targeting Vascular Inflammation

    Testing canagliflozin to reduce blood vessel inflammation in cardiovascular disease

    💵 May compensate

    📍 University of Ottawa Heart Institute · Ottawa, Ontario · Get directions →

    CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs.

    ✓ Study care freePhase 2Ages 18+Learn more →